Antihistone and Antispliceosomal Antibodies

Systemic Lupus Erythematosus

Volumn , Issue , 2011, Pages 275-292

  Satoh, Minoru ^a   Fritzler, Marvin J ^b   Chan, Edward K L ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959815028     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374994-9.10016-6     Document Type: Chapter

References (137)

1. Tan E.M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989, 44:93-151.
2. Hardin J.A. The lupus autoantigens and the pathogenesis of systemic lupus erythematosus. Arthritis Rheum 1986, 29:457-460.
3. Tan E.M., Chan E.K.L., Sullivan K.F., Rubin R.L. Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol 1988, 47:121-141.
4. Hargraves M.M., Richmond H., Morton R. Presentation of two bone marrow elements: the "Tart" cell and the "L.E." cell. Proc. Staff Mtg. Mayo Clinic 1948, 23:25-28.
5. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., Schaller J.G., Talal N., Winchester R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
6. Holman H., Deicher H.R. The reaction of the lupus erythematosus (L.E.) cell factor with deoxyribonucleoprotein of the cell nucleus. J Clin Invest 1959, 38:2059-2072.
7. Holman H.R., Deicher H.R.G., Kunkel H.G. The L.E. cell and the L.E. serum factors. Bull N Y Acad Med 1959, 35:409-418.
8. Holborow E.J., Weir D.M. Histone: An essential component for the lupus erythematosus antinuclear reaction. Lancet 1959, 1:809.
9. Aisenberg A.C. Studies on the mechanism of the lupus erythematosus (L.E.) phenomenon. J Clin Invest 1959, 38:325.
10. Hannestad K., Rekvig O.P., Husebekk A. Cross-reacting rheumatoid factors and lupus erythematosus (LE)-factors. Springer Semin Immunopathol 1981, 4:133.
11. Rekvig O.P., Hannestad K. Lupus erythematosus (LE) factors recognize both nucleosomes and viable human leukocytes. Scand J Immunol 1981, 13:597.
12. Schett G., Steiner G., Smolen J.S. Nuclear antigen histone H1 is primarily involved in lupus erythematosus cell formation. Arthritis Rheum 1998, 41:1446-1455.
13. Schett G., Rubin R.L., Steiner G., Hiesberger H., Muller S., Smolen J. The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. Arthritis Rheum 2000, 43:420-428.
14. Fritzler M.J., Chan E.K.L., Lahita R.G. Antibodies to nonhistone antigens in systemic lupus erythematosus. Systemic Lupus Erythematosus 2004, 348-376. Elsevier Academic Press, San Diego.
15. Pruss D., Bartholomew B., Persinger J., Hayes J., Arents G., Moudrianakis E.N., Wolffe A.P. An asymmetric model for the nuclesome: a binding site for linker histones inside the DNA gyres. Science 1996, 274:614-617.
16. Godfrey J.E., Baxevanis A.D., Moudrianakis E.N. Spectropolarimetric analysis of the core histone octamer and its subunits. Biochemistry 1990, 29:965-972.
17. Fritzler M.J., Rose N.R., de Macario E.C., Folds J.D. Immunofluorescent antinuclear antibody test. Manual of Clinical Laboratory Immunology 1997, 920-927. American Society for Microbiology, Washington, D.C.
18. Chan E.K.L., Fritzler M.J., Wiik A., Andrade L.E., Reeves W.H., Tincani A., Meroni P.L. AutoAbSC.Org - Autoantibody Standardization Committee in 2006. Autoimmun Rev 2007, 6:577-580.
19. von Muhlen C.A., Tan E.M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin. Arthritis Rheum 1995, 24:323-358.
20. Ochs R.L., Muro Y., Si Y., Ge H., Chan E.K.L., Tan E.M. Autoantibodies to DFS70/transcriptional coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 2000, 105:1211-1220.
21. Caturla A., Colome J.A., Bustos A., Chamorro M.J., Figueredo M.A., Subiza J.L., de la Concha E.G. Occurrence of antibodies to protease treated histones in a patient with vasculitis. Clin Immunol Immunopathol 1991, 60:65-71.
22. Portanova J.P., Rubin R.L., Joslin F.G., Agnello V.D., Tan E.M. Reactivity of anti-histone antibodies induced by procainamide and hydralazine. Clin Immunol Immunopathol 1982, 25:67-79.
23. Molden D.P., Klipple G.L., Peebles C.L., Rubin R.L., Nakamura R.M., Tan E.M. IgM anti-histone H-3 antibody associated with undifferentiated rheumatic disease syndromes. Arthritis Rheum 1986, 29:39-43.
24. Pauls J.D., Silverman E., Laxer R.M., Fritzler M.J. Antibodies to histones H1 and H5 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum 1989, 32(7):877-883.
25. Burlingame R.W., Rubin R.L. Subnucleosome structures as substrates in enzyme-linked immunosorbent assays. J Immunol Methods 1990, 134:187-199.
26. Fritzler M.J., Rubin R.L. Antibodies to histones and nucleosome-related antigens. Dubois' Lupus Erythematosus 2007, 464-486. Lippincott Williams & Wilkins, Philadelphia, PA. D.J. Wallace, B.H. Hahn (Eds.).
27. Rubin R.L., Theofilopoulos A.N. Monoclonal autoantibodies reacting with multiple structurally related and unrelated macromolecules. Intern Rev Immunol 1987, 3:71-95.
28. Subiza J.L., Caturla A., Pascual-salcedo D., Chamorro M.J., Gazapo E., Figueredo M.A., et al. DNA-anti-DNA complexes account for part of the antihistone activity found in patients with systemic lupus erythematosus. Arthritis Rheum 1989, 32(4):406-412.
29. Suzuki T., Burlingame R.W., Casiano C.A., Boey M.L., Rubin R.L. Antihistone antibodies in systemic lupus erythematosus: Assay dependency and effects of ubiquitination and serum DNA. J Rheumatol 1994, 21:1081-1091.
30. Schmiedeke T.M.J., Stockl F.W., Weber R., Sugisaki Y., Batsford S.R., Vogt A. Histones Have High-Affinity for the Glomerular Basement-Membrane - Relevance for Immune-Complex Formation in Lupus Nephritis. J Exp Med 1989, 169:1879-1894.
31. Burlingame R.W. Recent advances in understanding the clinical utility and underlying cause of antinucleosome (antichromatin) autoantibodies. Clin Appl Immunology Reviews 2004, 4:351-366.
32. Czaja A.J., Ming C., Shirai M., Nishioka M. Frequency and significance of antibodies to histones in autoimmune hepatitis. J Hepatol 1995, 23:32-38.
33. Chen M., Shirai M., Czaja A.J., Kurokohchi K., Arichi T., Arima K., et al. Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998, 13:483-489.
34. Klajman A., Kafri B., Shohat T., Drucker I., Moalem T., Jaretzky A. The prevalence of antibodies to histones induced by procainamide in old people, in cancer patients, and in rheumatoid-like diseases. Clin Immunol Immunopathol 1983, 27:1-8.
35. Burlingame R.W., Boey M.L., Starkebaum G., Rubin R.L. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994, 94:184-192.
36. Massa M., De Benedetti F., Pignatti P., Albani S., Di Fuccia G., Monestier M., et al. Anti-double stranded DNA, anti-histone, and anti-nucleosome IgG reactivities in children with systemic lupus erythematosus. Clin Exp Rheumatol 1994, 12:219-225.
37. Li L., Chen M., Huang D.Y., Nishioka M. Frequency and significance of antibodies to chromatin in autoimmune hepatitis type I. J Gastroenterol Hepatol 2000, 15:1176-1182.
38. Czaja A.J., Shums Z., Binder W.L., Lewis S.J., Nelson V.J., Norman G.L. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci 2003, 48:1658-1664.
39. Sato S., Kodera M., Hasegawa M., Fujimoto M., Takehara K. Antinucleosome antibody is a major autoantibody in localized scleroderma. Br J Dermatol 2004, 151:1182-1188.
40. Amoura Z., Koutouzov S., Chabre H., Cacoub P., Amoura I., Musset L., et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000, 43:76-84.
41. Wallace D.J., Lin H.C., Shen G.Q., Peter J.B. Antibodies to histone (H2A-H2B)-DNA complexes in the absence of antibodies to double-stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus. Arthritis Rheum 1994, 37:1795-1797.
42. Ghirardello A., Doria A., Zampieri S., Tarricone E., Tozzoli R., Villalta D., et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimmun 2004, 22:235-240.
43. Cairns A.P., McMillan S.A., Crockard A.D., Meenagh G.K., Duffy E.M., Armstrong D.J., et al. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 2003, 62:272-273.
44. Simon J.A., Cabiedes J., Ortiz E., Alcocer-Varela J., Sanchez-Guerrero J. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology. (Oxford) 2004, 43:220-224.
45. Chabre H., Amoura Z., Piette J.C., Godeau P., Bach J.F., Koutouzov S. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995, 38:1485-1491.
46. Amoura Z., Piette J.C., Chabre H., Cacoub P., Papo T., Wechsler B., et al. Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum 1997, 40:2217-2225.
47. Cervera R., Vinas O., Ramos-Casals M., Font J., Garcia-Carrasco M., Siso A., et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 2003, 62:431-434.
48. Bruns A., Blass S., Hausdorf G., Burmester G.R., Hiepe F. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 2000, 43:2307-2315.
49. Min D.J., Kim S.J., Park S.H., Seo Y.I., Kang H.J., Kim W.U., et al. Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin Exp Rheumatol 2002, 20:13-18.
50. Stinton L.M., Barr S.G., Tibbles L.A., Sar A., Benedikttson H., Fritzler M.J. Autoantibodies in lupus nephritis patients requiring renal transplantation. Lupus 2007, 16:394-400.
51. Benucci M., Gobbi F.L., Del Rosso A., Cesaretti S., Niccoli L., Cantini F. Disease activity and antinucleosome antibodies in systemic lupus erythematosus. Scand J Rheumatol 2003, 32:42-45.
52. Lacotte S., Dumortier H., Decossas M., Briand J.P., Muller S. Identification of New Pathogenic Players in Lupus: Autoantibody-Secreting Cells Are Present in Nephritic Kidneys of (NZBxNZW)F1 Mice. J Immunol 2010.
53. van Bavel C.C., Dieker J., Muller S., Briand J.P., Monestier M., Berden J.H., et al. Apoptosis-associated acetylation on histone H2B is an epitope for lupus autoantibodies. Mol Immunol 2009, 47:511-516.
54. Kiss E., Lakos G., Szegedi G., Poor G., Szodoray P. Anti-nuscleosome antibody, a reliable indicator for lupus nephritis. Autoimmunity 2009, 42:393-398.
55. Totoritis M.C., Tan E.M., McNally E.M., Rubin R.L. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N Engl J Med 1988, 318:1431-1436.
56. Mongey A.B., Donovan-Brand R., Thomas T.J., Adams L.E., Hess E.V. Serologic evaluation of patients receiving procainamide. Arthritis Rheum 1992, 35:219-223.
57. Rubin R.L., McNally E.M., Nusinow S.R., Robinson C.A., Tan E.M. IgG antibodies to the histone complex H2A-H2B characterize procainamide-induced lupus. Clin Immunol Immunopathol 1985, 36:49-59.
58. Hobbs R.N., Clayton A.L., Bernstein R.M. Antibodies to the five histones and poly(adenosine diphosphate-ribose) in drug induced lupus: Implications for pathogenesis. Ann Rheum Dis 1987, 46:408-416.
59. Burlingame R.W., Rubin R.L. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 1991, 88:680-690.
60. Rubin R.L., Nusinow S.R., Johnson A.D., Rubenson D.S., Curd J.G., Tan E.M. Serological changes during induction of lupus-like disease by procainamide. Am J Med 1986, 80:999-1002.
61. Rubin R.L., Burlingame R.W., Arnott J.E., Totoritis M.C., McNally E.M., Johnson A.D. IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus. J Immunol 1995, 154:2483-2493.
62. Burlingame R.W., Rubin R.L., Balderas R.S., Theofilopoulos A.N. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 1993, 91:1687-1696.
63. Tan E.M., Kunkel H.G. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol 1966, 96:464-471.
64. Craft J. Antibodies to snRNPs in systemic lupus erythematosus. Rheum Dis Clin North Am. 1992, 18:311-335.
65. Lerner M.R., Steitz J.A. Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 1979, 76:5495-5499.
66. Mimori T., Hinterberger M., Pettersson I., Steitz J.A. Autoantibodies to the U2 small nuclear ribonucleoprotein in a patient with scleroderma-polymyositis overlap syndrome. J Biol Chem. 1984, 259:560-565.
67. Craft J., Mimori T., Olsen T.L., Hardin J.A. The U2 small nuclear ribonucleoprotein particle as an autoantigen. J Clin Invest 1988, 81:1716-1724.
68. Satoh M., Langdon J.J., Hamilton K.J., Richards H.B., Panka D., Eisenberg R.A., Reeves W.H. Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein. J Clin Invest 1996, 97:2619-2626.
69. Okano Y., Targoff I.N., Oddis C.V., Fujii T., Kuwana M., Tsuzaka K., Hirakata M., Mimori T., Craft J., Medsger J.T.A. Anti-U5 small nuclear ribonucleoprotein(snRNP) antibodies: A rare anti-U snRNP specificity. Clin Immunol Immunopathol 1996, 81:41-47.
70. Satoh M., Richards H.B., Hamilton K.J., Reeves W.H. Human anti-nuclear ribonucleoprotein antigen autoimmune sera contain a novel subset of autoantibodies that stabilizes the molecular interaction of U1RNP-C protein with the Sm core proteins. J Immunol 1997, 158:5017-5025.
71. Mahler M., Fritzler M.J. Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci 2010, 1183:267-287.
72. Yamasaki Y., Narain S., Yoshida H., Hernandez L., Barker T., Hahn P.C., et al. Autoantibodies to RNA helicase A: A new serological marker of early lupus. Arthritis Rheum 2007, 56:596-604.
73. Brahms H., Raker V.A., van Venrooij W.J., Luhrmann R. A major, novel systemic lupus erythematosus autoantibody class recognizes the E, F, and G Sm snRNP proteins as an E-F-G complex but not in their denatured states. Arthritis Rheum 1997, 40:672-682.
74. Satoh M., Akaogi J., Kuroda Y., Nacionales D.C., Yoshida H., Yamasaki Y., et al. Autoantibodies that stabilize U1snRNPs are a significant component of human autoantibodies to snRNPs and delay proteolysis of the Sm antigens. J Rheumatol 2004, 31:2382-2389.
75. Takeda Y., Wise K.S., Wang G., Grady G., Hess E.V., Sharp G.C., et al. Human autoantibodies recognizing a native, macromolecular structure composed of Sm core proteins in U small nuclear RNP particles. Arthritis Rheum 1998, 41:2059-2067.
76. Salgado-Garrido J., Bragado-Nilsson E., Kandels-Lewis S., Seraphin B. Sm and Sm-like proteins assemble in two related complexes of deep evolutionary origin. EMBO J 1999, 18:3451-3462.
77. Eystathioy T., Peebles C.L., Hamel J.C., Vaughn J.H., Chan E.K. Autoantibody to hLSm4 and the heptameric LSm complex in anti-Sm sera. Arthritis Rheum 2002, 46:726-734.
78. Sharp G.C., Irvin W.S., LaRoque R.L., Velez C., Daly V., Kaiser A.D., et al. Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy. J Clin Invest 1971, 50:350-359.
79. Fritzler M.J. Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. Lupus 2006, 15:422-427.
80. Mattioli M., Reichlin M. Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera. J Immunol 1971, 107:1281-1290.
81. Sharp G.C., Irvin W.S., Tan E.M., Gould R.G., Holman H.R. Mixed connective tissue disease-An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972, 52:148-159.
82. Mosca M., Baldini C., Bombardieri S. Undifferentiated connective tissue diseases in 2004. Clin Exp Rheumatol 2004, 22:S14-18.
83. Mosca M., Tavoni A., Neri R., Bencivelli W., Bombardieri S. Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year. Lupus 1998, 7:95-100.
84. Satoh M., Chan E.K.L., Sobel E.S., Kimpel D.L., Yamasaki Y., Narain S., Mansoor R., Reeves W.H. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol 2007, 3:721-738.
85. Murakami A., Kojima K., Ohya K., Imamura K., Takasaki Y. A new conformational epitope generated by the binding of recombinant 70-kd protein and U1 RNA to anti-U1 RNP autoantibodies in sera from patients with mixed connective tissue disease. Arthritis Rheum 2002, 46:3273-3282.
86. Mahler M., Fritzler M.J., Bluthner M. Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res Ther 2005, 7:R19-29.
87. Brahms H., Raymackers J., Union A., de Keyser F., Meheus L., Luhrmann R. The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies. J Biol Chem 2000, 275:17122-17129.
88. Fritzler M.J., Fritzler M.L. Microbead-based technologies in diagnostic autoantibody detection. Expert Opin Med Diag 2009, 3:81-89.
89. Fritzler M.J., Fritzler M.L. The emergence of multiplexed technologies as diagnostic platforms in systemic autoimmune diseases. Curr Med Chem 2006, 13:2503-2512.
90. Clegg D.O., Williams H.J., Singer J.Z., Steen V.D., Schlegel S., Ziminski C., et al. Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 1991, 18:1340-1343.
91. Vaz C.C., Couto M., Medeiros D., Miranda L., Costa J., Nero P., et al. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol 2009, 28:915-921.
92. Danieli M.G., Fraticelli P., Franceschini F., Cattaneo R., Farsi A., Passaleva A., Pietrogrande M., Invernizzi F., Vanoli M., Scorza R., Sabbadini M.G., Gerli R., Corvetta A., Farina G., Salsano F., Priori R., Valesini G., Danieli G. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol 1999, 17:585-591.
93. Kameda H., Kuwana M., Hama N., Kaburaki J., Homma M. Coexistence of serum anti-DNA topoisomerase I and anti-Sm antibodies: report of 3 cases. J Rheumatol 1997, 24:400-403.
94. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., Harley J.B. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
95. Satoh M., Yamagata H., Watanabe F., Matsushita Y., Sakamoto K., Yoshida K., Nakayama S., Akizuki M. A case of long-standing classical rheumatoid arthritis complicated by serological and clinical characteristics of systemic lupus erythematosus. Scand J Rheumatol 1993, 22:138-140.
96. Elkon K.B., Bonfa E., Llovet R., Eisenberg R.A. Association between anti-Sm and anti-ribosomal P protein autoantibodies in human systemic lupus erythematosus and MRL/lpr mice. J Immunol 1989, 143:1549-1554.
97. Caponi L., Bombardieri S., Migliorini P. Anti-ribosomal antibodies bind the Sm proteins D and B/B'. Clin Exp Immunol 1998, 112:139-143.
98. Reichlin M., Martin A., Taylor-Albert E., Tsuzaka K., Zhang W., Reichlin M.W., Koren E., Ebling F.M., Tsao B., Hahn B.H. Lupus autoantibodies to native DNA cross-react with the A and D snRNP polypeptides. J Clin Invest 1994, 93:443-449.
99. Sharp G.C., Irvin W.S., May C.M., Holman H.R., McDuffie F.C., Hess E.V., Schmid F.R. Association of autoantibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systemic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976, 295:1149-1154.
100. Homma M., Mimori T., Takeda Y., Akama H., Yoshida T., Ogasawara T., Akizuki M. Autoantibodies to the Sm antigen: Immunological approach to clinical aspects of systemic lupus erythematosus. J Rheumatol 1987, 14(suppl):188-193.
101. Pettersson I., Wang G., Smith E.I., Wigzell H., Hedfors E., Horn J., Sharp G.C. The use of immunoblotting and immunoprecipitation of (U) small nuclear ribonucleoproteins in the analysis of sera of patients with mixed connective tissue disease and systemic lupus erythematosus. Arthritis Rheum 1986, 29:986-996.
102. Takeda Y., Wang G.S., Wang R.J., Anderson S.K., Petterson I., Amaki S., Sharp G.C. Enzyme-linked immunosorbent assay using isolated(U) small nuclear ribonucleoprotein polypeptides as antigens to investigate the clinical significance of autoantibodies to these polypeptides. Clin Immunol Immunopathol 1989, 50:213-220.
103. St Clair E.W., Query C.C., Bentley R., Keene J.D., Polisson R.P., Allen N.B., Caldwell D.S., Rice J.R., Cox C., Pisetsky D.S. Expression of autoantibodies to recombinant (U1) RNP-associated 70K antigen in systemic lupus erythematosus. Clin Immunol Immunopathol 1990, 54:266-280.
104. Habets W.J., Hoet M.H., van Venrooij W.J. Epitope patterns of anti-RNP antibodies in rheumatic diseases. Evidence for an antigen-driven autoimmune response. Arthritis Rheum 1990, 33:834-841.
105. Habets W., Hoet M., Bringmann P., Luhrmann R., van Venrooij W. Autoantibodies to ribonucleoprotein particles containing U2 small nuclear RNA. EMBO J 1985, 4:1545-1550.
106. Reeves W.H., Fisher D.E., Wisniewolski R., Gottlieb A.B., Chiorazzi N. Psoriasis and Raynaud's phenomenon associated with autoantibodies to U1 and U2 small nuclear ribonucleoproteins. N Engl J Med 1986, 315:105-111.
107. Okano Y., Medsger T.A.J. Newly identified U4/U6 snRNP-binding proteins by serum autoantibodies from a patient with systemic sclerosis. J Immunol 1991, 146:535-542.
108. Fujii T., Mimori T., Hama N., Suwa A., Akizuki M., Tojo T., Homma M. Characterization of autoantibodies that recognize U4/U6 small ribonucleoprotein particles in serum from a patient with primary Sjogren's syndrome. J Biol Chem. 1992, 267:16412-16416.
109. Okano Y., Medsger T.A.J. Novel human autoantibodies reactive with 5'-terminal trimethylguanosine cap structures of U small nuclear RNA. J Immunol 1992, 149:1093-1098.
110. Gilliam A.C., Steitz J.A. Rare scleroderma autoantibodies to the U11 small nuclear ribonucleoprotein and to the trimethylguanosine cap of U small nuclear RNAs. Proc Natl Acad Sci USA 1993, 90:6781-6785.
111. Okano Y., Steen V.D., Medsger T.A.J. Autoantibody to U3 nucleolar ribonucleoprotein(fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992, 35:95-100.
112. Wilusz J., Keene J.D. Autoantibodies specific for U1 RNA and initiator methionine tRNA. J Biol Chem. 1986, 261:5467-5472.
113. Hoet R.M., Koornneef I., de Rooij D.J., van de Putte L.B., van Venrooij W.J. Changes in anti-U1 RNA antibody levels correlate with disease activity in patients with systemic lupus erythematosus overlap syndrome. Arthritis Rheum 1992, 35:1202-1210.
114. Maddison P.J., Reichlin M. Quantitation of precipitating antibodies to certain soluble nuclear antigens in SLE. Arthritis Rheum 1977, 20:819-824.
115. Taylor R.P., Horgan C. Quantitative determination of anti-dsDNA antibodies and antibody/dsDNA stoichiometries in prepared, soluble complement-fixing antibody/dsDNA immune complexes. Mol Immunol 1984, 21:853-862.
116. Nishikai M., Okano Y., Mukohda Y., Sato A., Ito M. Serial estimation of anti-RNP antibody titers in systemic lupus erythematosus, mixed connective tissue disease and rheumatoid arthritis. J Clin Lab Immunol 1984, 13:15-19.
117. Manz R.A., Hauser A.E., Hiepe F., Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 2005, 23:367-386.
118. Cambridge G., Leandro M.J., Teodorescu M., Manson J., Rahman A., Isenberg D.A., Edwards J.C. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006, 54:3612-3622.
119. Vallerskog T., Gunnarsson I., Widhe M., Risselada A., Klareskog L., van Vollenhoven R., Malmstrom V., Trollmo C. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007, 122:62-74.
120. Ohosone Y., Mimori T., Fujii T., Akizuki M., Matsuoka Y., Irimajiri S., Hardin J.A., Craft J., Homma M. Autoantigenic epitopes of the B polypeptide of Sm small nuclear RNP particles. Identification of regions accessible only within the U1 small nuclear RNP. Arthritis Rheum 1992, 35:960-966.
121. Mimori T., Ogasawara T. The structure and antigenic epitopes of U1 small nuclear ribonucleoprotein. Mixed Connective Tissue Disease and Anti-nuclear Antibodies 1987, 169-174. Elsevier, Amsterdam. R. Kasukawa, G.C. Sharp (Eds.).
122. James J.A., Harley J.B., Scofield R.H. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006, 18:462-467.
123. James J.A., Mamula M.J., Harley J.B. Sequential autoantigenic determinants of the small nuclear ribonucleoprotein Sm D shared by human lupus autoantibodies and MRL lpr/lpr antibodies. Clin Exp Immunol 1994, 98:419-426.
124. Harley J.B., James J.A. Autoepitopes in lupus. J Lab Clin Med 1995, 126:509-516.
125. Query C.C., Keene J.D. A human autoimmune protein associated with U1 RNA contains a region of homology that is crossreactive with retroviral p30gag antigen. Cell 1987, 51:211-220.
126. Lipes J., Skamene E., Newkirk M.M. The genotype of mice influences the autoimmune response to spliceosome proteins induced by cytomegalovirus gB immunization. Clin Exp Immunol 2002, 129:19-26.
127. Greidinger E.L., Foecking M.F., Ranatunga S., Hoffman R.W. Apoptotic U1-70 kd is antigenically distinct from the intact form of the U1-70-kd molecule. Arthritis Rheum 2002, 46:1264-1269.
128. Peng S.L., Moslehi J., Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 1997, 99:1936-1946.
129. Richards H.B., Satoh M., Jennete J.C., Croker B.P., Yoshida H., Reeves W.H. Interferon g is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int 2001, 60:2173-2180.
130. Calvani N., Satoh M., Croker B.P., Reeves W.H., Richards H.B. Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus. Kidney Int 2003, 64:897-905.
131. Nacionales D.C., Kelly-Scumpia K.M., Lee P.Y., Weinstein J.S., Lyons R., Sobel E., Satoh M., Reeves W.H. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 2007, 56:3770-3783.
132. Kirou K.A., Lee C., George S., Louca K., Peterson M.G., Crow M.K. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503.
133. Zhuang H., Narain S., Sobel E., Lee P.Y., Nacionales D.C., Kelly K.M., Richards H.B., Segal M., Stewart C., Satoh M., Reeves W.H. Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin Immunol 2005, 117:238-250.
134. Lee P.Y., Kumagai Y., Li Y., Takeuchi O., Yoshida H., Weinstein J., Kellner E.S., Nacionales D., Barker T., Kelly-Scumpia K., van Rooijen N., Kumar H., Kawai T., Satoh M., Akira S., Reeves W.H. TLR7-dependent and FcγR-independent production of type I interferon in experimental mouse lupus. J Exp Med 2008, 205:2995-3006.
135. Alarcon-Segovia A., Ruiz-Arguelles A., Llorence L. Broken dogma: penetration of autoantibodies into living cells. Immunol Today 1996, 17:163-164.
136. Vollmer J., Tluk S., Schmitz C., Hamm S., Jurk M., Forsbach A., Akira S., Kelly K.M., Reeves W.H., Bauer S., Krieg A.M. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005, 202:1575-1585.
137. Fatenejad S., Mamula M., Craft J. Role of intermolecular/intrastructural B and T-cell determinants in the diversification of autoantibodies to ribonucleoprotein particles. Proc Natl Acad Sci USA 1993, 90:12010-12014.